Healthcare
Revolution Medicines, Inc.(RVMD)
Live Price
Offline$162.99
+3.31% today
Window Change
+3.50%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $31.44B
- Revenue Growth
- 0.0%
- EPS Growth
- -66.2%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Revolution Medicines, Inc. (RVMD) is a Healthcare stock with a market cap of $31.44B and listed on NASDAQ. The stock last traded around $162.99 and up 3.5% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -66.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -66.2%, free cash flow -60.9% with operating margin 0.0% and ROIC -56.8%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RVMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -66.2%, with operating margin around 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVMD
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RVMD Max Drawdown
-11.91%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RVMD and SPY.
Company Overview
Revolution Medicines, Inc.
NASDAQ Global Select
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
- Leadership
- Mark A. Goldsmith
- IPO Date
- Feb 13, 2020
- Employees
- 616
- Street Address
- 700 Saginaw Drive
- Mailing
- Redwood City, CA, 94063
- Region
- Redwood City, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 481 6801
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 17.2
Growth
- Revenue
- 0.0%
- EPS
- -66.2%
- Free Cash Flow
- -60.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -63.1%
- ROIC
- -56.8%
Balance Sheet
- Debt/Equity
- 0.10
- Current Ratio
- 7.14
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.